Saturday 17 October 2026 Export RBOT’s income statement to Excel — free account

Vicarious Surgical Inc.

In the quarter to March 2026, EPS grew 60.4% and free cash flow grew 47.3%, each against the same quarter a year earlier.

0.02 0.06 −75.00%

Follow RBOT

Alert me

Market cap: $14.3M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.01

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	2	—	2	—	—	—	—	—	—	—	—

Insider Ownership 41.43%

Capital & Financial Ratios $m

Market Cap 14.31

Revenue —

Net Income (42.12)

Free Cash Flow (39.64)

Net Debt (3.68)

Current Ratio 1.54

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.04

Past 5Y EPS Growth —

This Y EPS Growth 24.74%

Next Y EPS Growth 49.69%

Next Y revenue growth —

Next 5Y EPS Growth 41.34%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 0.07%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	98	49	10	4
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	101	52	12	5

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	0
	7	8	4	3

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(10.20%)	(55.42%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	—	—	—	—
’25	(12)	(14)	(10)	(9)	(45)
’24	(14)	(11)	(13)	(12)	(50)
’23	(19)	(15)	(17)	(11)	(62)
’22	(15)	(14)	(14)	(18)	(61)
’21	(4)	(6)	(14)	(10)	(33)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	—	—	—	—
’25	(12)	(14)	(11)	(9)	(45)
’24	(14)	(11)	(13)	(12)	(50)
’23	(19)	(15)	(17)	(12)	(64)
’22	(17)	(16)	(15)	(19)	(67)
’21	(4)	(6)	(14)	(11)	(35)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.03)	—	—	—	—
’25	(2.60)	(2.23)	(1.86)	(1.57)	(8.19)
’24	(3.00)	(2.59)	(2.90)	(2.36)	(10.74)
’23	(6.31)	(3.60)	(3.00)	(1.80)	(14.71)
’22	9.91	(0.30)	(6.01)	(2.70)	1.20
’21	(1.80)	(2.27)	(14.69)	7.82	(10.93)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	288.00	285.00	50.70	6.00	4.27	1.81	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	306.00	473.58	323.70	106.65	21.42	18.97
People
People	Employees	—	—	—	—	3	165	213	131	123	26
	Revenue/emp, $m	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	—	—	0.00	0.00	—	—	—
	EBT	—	—	—	—	(13)	(35)	5	(71)	(63)	(50)
	EBT margin, %	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	—	0	(13)	(35)	5	(71)	(63)	(50)
	Depreciation	—	—	—	—	0	0	1	2	2	1
Per share, $
Per share, $	Revenue	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	—	(4.91)	(10.93)	1.20	(14.71)	(10.74)	(8.19)
	Cash flow	—	—	—	—	(4.59)	(10.34)	(15.09)	(12.80)	(8.49)	(7.35)
	Capex	—	—	—	—	(0.05)	(0.40)	(1.32)	(0.34)	(0.03)	(0.02)
	Free cash flow	—	—	—	—	(4.64)	(10.74)	(16.41)	(13.14)	(8.52)	(7.37)
	Book value	—	—	—	—	6.43	25.81	27.38	20.13	7.93	1.61
	Shares, m	—	—	—	—	3	3	4	5	6	6
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	(12)	(33)	(61)	(62)	(50)	(45)
	Capex	—	—	—	—	0	(1)	(5)	(2)	0	0
	Free cash flow	—	—	—	—	(12)	(35)	(67)	(64)	(50)	(45)
Balance, $m
Balance, $m	Working capital	—	—	—	—	16	172	112	94	44	8
	Total debt	—	—	—	—	—	1	16	—	—	—
	Net debt	—	—	—	—	(17)	(172)	(116)	(98)	(49)	(10)
	Shareholders’ equity	—	—	—	—	17	83	111	98	47	10
Returns, %
Returns, %	ROA	—	—	—	0.00	(144.76)	(35.30)	3.20	(54.64)	(67.41)	(114.96)
	ROIC	—	—	—	—	0.00	0.00	0.00	0.00	0.00	(63,809.95)
	ROE	—	—	—	—	(29.23)	(70.45)	5.31	(68.01)	(87.40)	(177.51)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BDMD Baird Medical Investment Holdings Limited	$19.2M	— (loss-making)	—	—	n/m	−598.12% (below 0%: shrinking)	—	—	Compare
LFWD Lifeward Ltd.	$17.2M	— (loss-making)	— (loss-making)	+15.71% (above 0%: growing)	n/m	−52.77% (below 0%: shrinking)	40.90%	(62.69%)	Compare
ALUR Allurion Technologies, Inc.	$16.7M	— (loss-making)	— (loss-making)	−47.19% (below 0%: shrinking)	n/m	+65.98% (above 0%: growing)	41.70%	(126.60%)	Compare
HSCS HeartSciences Inc.	$15.4M	— (loss-making)	— (loss-making)	−46.15% (below 0%: shrinking)	n/m	+18.18% (above 0%: growing)	61.90%	(139,957.14%)	Compare
IRIX IRIDEX Corporation	$14.5M	— (loss-making)	— (loss-making)	−7.41% (below 0%: shrinking)	n/m	+130.24% (above 0%: growing)	34.19%	(8.19%)	Compare
RBOT Vicarious Surgical Inc.	$14.3M	— (loss-making)	—	—	n/m	+47.33% (above 0%: growing)	0.00%	0.00%
SINT SINTX TECHNOLOGIES, INC.	$13.4M	— (loss-making)	— (loss-making)	+199.34% (above 0%: growing)	n/m	−38.60% (below 0%: shrinking)	61.50%	(638.94%)	Compare
PETV PetVivo Holdings, Inc.	$12.9M	— (loss-making)	— (loss-making)	+13.48% (above 0%: growing)	n/m	+40.13% (above 0%: growing)	66.14%	(476.54%)	Compare
BTCY Biotricity Inc.	$10.9M	— (loss-making)	— (loss-making)	+10.40% (above 0%: growing)	n/m	+235.83% (above 0%: growing)	82.55%	3.70%	Compare
Median of peers	$15.0M	—	—	+10.40%	—	+29.16%	61.50%	(126.60%)

All 149 Medical Devices stocks →

Vicarious Surgical Inc. (RBOT) key facts

Vicarious Surgical Inc. (RBOT) is a Medical Devices company in the Healthcare sector.
As of October 16, 2026, RBOT traded at $0.02, a market capitalization of $14.3 million.
Return on equity was −177.5% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.